Duloxetine for the treatment of generalized anxiety disorder: a review

Ahsan Y Khan, Matthew MacalusoDepartment of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine-Wichita, Wichita, KS, USAAbstract: Approximately 16 million people in the United States suffer from anxiety disorders alone, while another 12 million experience both anxiety and at...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ahsan Y Khan, Matthew Macaluso
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/f63f5d7fc50b4c749c15dcfa5823076f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f63f5d7fc50b4c749c15dcfa5823076f
record_format dspace
spelling oai:doaj.org-article:f63f5d7fc50b4c749c15dcfa5823076f2021-12-02T02:54:36ZDuloxetine for the treatment of generalized anxiety disorder: a review1176-63281178-2021https://doaj.org/article/f63f5d7fc50b4c749c15dcfa5823076f2008-12-01T00:00:00Zhttp://www.dovepress.com/duloxetine-for-the-treatment-of-generalized-anxiety-disorder-a-review-a2740https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Ahsan Y Khan, Matthew MacalusoDepartment of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine-Wichita, Wichita, KS, USAAbstract: Approximately 16 million people in the United States suffer from anxiety disorders alone, while another 12 million experience both anxiety and at least one other psychiatric condition. Generalized anxiety disorder (GAD) has lifetime prevalence rates between 5% and 6%. Treatment of GAD is aimed primarily at symptom reduction. Duloxetine, a serotonin norepinephrine reuptake inhibitor (SNRI), received Food and Drug Administration (FDA) approval for the treatment of GAD in 2007. This article reviews the pharmacologic profile and seminal clinical trials associated with the FDA indication of duloxetine for GAD. A literature search performed using PubMed with the keywords “duloxetine”, “gad”, “generalized anxiety disorder”, and “venlafaxine XR” yielded 27 articles. We also focused on papers that pooled data from these seminal studies. Data on file from Eli Lilly were also reviewed, including data from the Eli Lilly website. Based on this search, duloxetine was found to be an FDA-approved treatment option for GAD that has been studied in several double-blind, placebo-controlled clinical trials. This review of duloxetine will help physicians to interpret clinical studies properly and also help them to make an informed decision about which patients are the most appropriate candidates for a trial of duloxetine.Keywords: duloxetine, generalized anxiety disorder, clinical trials, serotonin norepinephrine reuptake inhibitor (SNRI) Ahsan Y KhanMatthew MacalusoDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 23-31 (2008)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Ahsan Y Khan
Matthew Macaluso
Duloxetine for the treatment of generalized anxiety disorder: a review
description Ahsan Y Khan, Matthew MacalusoDepartment of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine-Wichita, Wichita, KS, USAAbstract: Approximately 16 million people in the United States suffer from anxiety disorders alone, while another 12 million experience both anxiety and at least one other psychiatric condition. Generalized anxiety disorder (GAD) has lifetime prevalence rates between 5% and 6%. Treatment of GAD is aimed primarily at symptom reduction. Duloxetine, a serotonin norepinephrine reuptake inhibitor (SNRI), received Food and Drug Administration (FDA) approval for the treatment of GAD in 2007. This article reviews the pharmacologic profile and seminal clinical trials associated with the FDA indication of duloxetine for GAD. A literature search performed using PubMed with the keywords “duloxetine”, “gad”, “generalized anxiety disorder”, and “venlafaxine XR” yielded 27 articles. We also focused on papers that pooled data from these seminal studies. Data on file from Eli Lilly were also reviewed, including data from the Eli Lilly website. Based on this search, duloxetine was found to be an FDA-approved treatment option for GAD that has been studied in several double-blind, placebo-controlled clinical trials. This review of duloxetine will help physicians to interpret clinical studies properly and also help them to make an informed decision about which patients are the most appropriate candidates for a trial of duloxetine.Keywords: duloxetine, generalized anxiety disorder, clinical trials, serotonin norepinephrine reuptake inhibitor (SNRI)
format article
author Ahsan Y Khan
Matthew Macaluso
author_facet Ahsan Y Khan
Matthew Macaluso
author_sort Ahsan Y Khan
title Duloxetine for the treatment of generalized anxiety disorder: a review
title_short Duloxetine for the treatment of generalized anxiety disorder: a review
title_full Duloxetine for the treatment of generalized anxiety disorder: a review
title_fullStr Duloxetine for the treatment of generalized anxiety disorder: a review
title_full_unstemmed Duloxetine for the treatment of generalized anxiety disorder: a review
title_sort duloxetine for the treatment of generalized anxiety disorder: a review
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/f63f5d7fc50b4c749c15dcfa5823076f
work_keys_str_mv AT ahsanykhan duloxetineforthetreatmentofgeneralizedanxietydisorderareview
AT matthewmacaluso duloxetineforthetreatmentofgeneralizedanxietydisorderareview
_version_ 1718402078675566592